Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data announced today that it was selected by the PCCTC to serve as a partner for its phase II clinical trial focused on identifying the most effective treatment for prostate cancer patients with genomic evidence of problems with DNA repair.